Alternatives to Duloxetine for Nerve and Chronic Pain

First-Line Alternatives to Duloxetine

Pregabalin is established as effective for neuropathic pain with Level A evidence, improving quality of life and reducing sleep interference, though the effect size is small, according to the American Academy of Physical Medicine and Rehabilitation 1
Gabapentin is probably effective for neuropathic pain with Level B evidence and is recommended as a first-line oral treatment for HIV-associated neuropathic pain by the Infectious Diseases Society of America 3, 1
The American Academy of Physical Medicine and Rehabilitation recommends dosing considerations for pregabalin, starting at lower doses and titrating to effective dose, typically 300-600 mg/day in divided doses 1
The Infectious Diseases Society of America and the American Academy of Physical Medicine and Rehabilitation suggest that gabapentin can be titrated to a maximum of 2400-3600 mg/day 3, 1
Both pregabalin and gabapentin may cause somnolence and dizziness, with side effects potentially being more severe in older individuals, as noted by the American Diabetes Association 2

Venlafaxine, another SNRI, has shown efficacy for neuropathic pain with Level B evidence, according to the American Academy of Physical Medicine and Rehabilitation and the European Society for Medical Oncology 1, 4
The European Society for Medical Oncology recommends starting venlafaxine at 50 mg initially, followed by 37.5 mg twice daily 4
The American Academy of Physical Medicine and Rehabilitation suggests that venlafaxine may be added to gabapentin for better response, with Level C evidence 1
Amitriptyline, a tricyclic antidepressant, has Level B evidence for neuropathic pain, with a starting dose of 10-25 mg/day, as recommended by the European Society for Medical Oncology and the American Diabetes Association 1, 2, 4

Capsaicin is available as an 8% patch or 0.075% cream, with the 8% patch having FDA approval for diabetic peripheral neuropathy pain, as noted by the American Diabetes Association 2
The American Diabetes Association recommends considering capsaicin for patients with contraindications to oral therapy or who prefer topical treatments 2
Topical menthol cream (1%) can be applied twice daily to the affected area and corresponding dermatomal region, as suggested by the European Society for Medical Oncology 4

Sodium valproate is probably effective for diabetic peripheral neuropathy, with Level B evidence, according to the American Academy of Physical Medicine and Rehabilitation 1
Sodium channel blockers have medium-quality evidence supporting their role in treating neuropathic pain, as noted by the American Diabetes Association 2
Tramadol shows moderate pain relief in diabetic peripheral neuropathy, but the American Diabetes Association cautions about the risk of addiction with opioid medications 1, 2

Venlafaxine may be added to gabapentin for enhanced response, with Level C evidence, as suggested by the American Academy of Physical Medicine and Rehabilitation 1

Oxcarbazepine, lamotrigine, and lacosamide should probably not be considered for diabetic peripheral neuropathy, with Level B evidence, according to the American Academy of Physical Medicine and Rehabilitation 1
The American Diabetes Association advises against using opioids for chronic neuropathic pain management due to the risk of addiction 2

Pregabalin and gabapentin have similar mechanisms but pregabalin has higher bioavailability and more predictable absorption, as noted by the American Academy of Physical Medicine and Rehabilitation 1

The American Academy of Physical Medicine and Rehabilitation and the American Diabetes Association recommend starting with pregabalin or gabapentin as first-line alternatives to duloxetine 1, 2
If response is inadequate, consider venlafaxine or amitriptyline, as suggested by the American Academy of Physical Medicine and Rehabilitation 1
For patients who cannot tolerate oral medications, consider topical treatments like capsaicin, as recommended by the American Diabetes Association 2
Allow 2-4 weeks at therapeutic doses to properly assess efficacy, as advised by the European Society for Medical Oncology 4